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Abstract
Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic
treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa
inhibitor. In all five patients haematological and biochemical parameters and adverse events were evaluated for a
period of twelve months.
Therapy with rivaroxaban was well tolerated in all cases and one patient showed a significant reduction of bleeding
and transfusion requirement. All patients obtained a significant reduction in days of hospitalization with a
consequent improvement in their quality of life after rivaroxaban treatment.
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Paroxysmal nocturnal haemoglobinuria (PNH) is a rare
acquired clonal disorder of hematopoietic cells character-
ized by a defect in the glycosylphosphatidylinositol (GPI)
anchored molecules due to a somatic mutation in the X
linked PIG-A gene. This leads to a partial or complete ab-
sence of two complement inhibitor GPI-linked proteins,
particularly CD59 and CD55, from the membrane of
the circulating cells, causing the activation of the
complement system on red cells surface and intravas-
cular haemolysis [1].
In addition to intravascular haemolytic anaemia, PNH
is characterized by hypercoagulable state and bone mar-
row aplasia. The hypercoagulable state is responsible for
life-threatening venous thrombosis generally arising in
hepatic, intra-abdominal, cerebral and extremity veins
and these thrombotic complications represent the most
common cause of death in patients with PNH [2].
Prophylactic anticoagulant treatment seems capable of
improving survival and morbidity [3]. Moreover, eculizu-
mab seems able to prevent thrombosis as an indirect
effect on intravascular haemolysis [4] and to reduce the
activation of coagulation [5].
We report the outcome of haematological and biochem-
ical parameters, recurrence of thrombotic and bleeding
events in five patients (Males = 1, Females = 4, mean age
47.4 years) with PNH and thrombotic complications eval-
uated for a period of twelve months both during warfarin,
a vitamin K antagonist (VKA), and rivaroxaban treatment.
Moreover, the assessment of occult blood in the stool was
performed monthly in all five evaluated patients. These
five patients were being treated with the monoclonal anti-
body eculizumab administered every 15 days during the
both VKA and rivaroxaban treatment.
Two patients received rivaroxaban at dosage of 15 mg
per day for previous bleeding complications observed dur-
ing the treatment with warfarin. The remaining three pa-
tients received rivaroxaban at a dosage of 20 mg per day.
The quantitative determination of rivaroxaban concen-
trations was assessed after 3 months of therapy using an
anti-factor Xa chromogenic assay (Biophen DiXal, Hy-
phen Biomed, France). Patients who received rivaroxa-
ban 15 mg per day showed, after 20 h from the drug
administration, a concentration of 10 and 14 ng/mL, re-
spectively. The remaining three patients who received
20 mg per day of rivaroxaban treatment had, after 20 h
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from the drug administration, concentrations of 17, 27
and 41 ng/mL, respectively. Therefore two patients re-
ceived a reduced dosage of rivaroxaban which, however,
can be utilized at this lower dose in patients with high
risk of haemorrhagic complications or impaired renal
function.
Since thrombotic complications occur frequently in un-
usual sites in patients with PNH, as reported in Table 1,
and rivaroxaban has no indication to be used in cerebral,
caval or portal vein thrombosis, we used, in this study, the
new oral direct anticoagulant in off label indications.
Haemoglobin levels and haematocrit values were stable
during the 12 months of rivaroxaban treatment (Table 1).
None out of five patients with PNH discontinued the ther-
apy with rivaroxaban for the occurrence of both throm-
botic or bleeding events. Patients one (Table 1) is a young
female patient with PNH and thrombotic complication
who after the beginning of anticoagulant treatment with
warfarin showed major bleeding due to severe menorrha-
gia that required red blood cell concentrates transfusion
even if the PT INR value was in the established range. In
this patient the administration of rivaroxaban instead of
warfarin led to a significant reduction in haemorrhagic
complication and transfusion requirement with a signifi-
cant improvement in her quality of life.
It is important to consider that patients with PNH are
forced to have a high number in days of hospitalization
per month in order to monitor the haematological pa-
rameters, to receive eculizumab therapy and to check
the anticoagulant treatment with VKA. The five patients
on therapy with rivaroxaban showed a significant reduc-
tion in days of hospitalization per months due to re-
duced controls for follow-up of the new antithrombotic
treatment (Table 1).
The quality of life (QOL) total score and the QOL
scores for each domain was determined in four out of
Table 1 Outcome of the evaluated parameters during twelve months of anticoagulant treatment with warfarin and rivaroxaban in
the patients with paroxysmal nocturnal haemoglobinuria
W R W R W R
Pt 1: Female, 45 yrs. Pt 2: Female, 66 yrs. Pt 3: Female, 45 yrs.
Thrombosis of superior sagittal sinus Thrombosis of portal vein Deep vein thrombosis
Haemoglobin (gr/dL) 7. 7± 0.4 8.4 ± 0.6 0.006 12.5 ± 0.6 13.1 ± 0.2 n. s. 7.9 ± 0.5 7.8 ± 0.6 n. s.
Haematocrit (%) 22.9 ± 2 25.4 ± 1.4 0.003 38.5 ± 1.4 39.4 ± 0.7 n. s. 27.8 ± 1.6 28.6 ± 2.8 n. s.
Platelets (× 103/μL) 81.9 ± 9.4 73.8 ± 10.3 n. s. 118.1 ± 24.2 112.3 ± 6.7 n. s. 357.2 ± 27.2 347.3 ± 28.8 n. s.
Lactate deydrogenase (IU/L) 326.7 ± 15.0 311.7 ± 11.4 n. s. 249.1 ± 44.4 257.3 ± 40.1 n. s. 331.6 ± 207.3 312.8 ± 177.3 n. s.
Bleeding Days 6.0 ± 0.8 3.6 ± 0.7 0.001
Low Molecular Weight Heparin
(Days of bridging-therapy)
8.2 ± 0.7 1.7 ± 1.1 < 0.001
Red Blood Cell Units transfused 11 4 0.03 0 0 6 6
Diapers (number) 14.9 ± 0.6 10 ± 0.8 < 0.001
Hospital admissions
(Days per month)
4.2 ± 0.7 2.7 ± 0.8 < 0.001 3.7 ± 0.6 2.8 ± 0.6 0.001 4.0 ± 0.7 2.6 ± 0.8 0.001
Pt 4: Male, 27 yrs. Pt 5: Female, 54 yrs. All patients
Thrombosis of portal vein Thrombosis of caval vein
Haemoglobin (gr/dL) 13.3 ± 0.6 13.6 ± 0.9 n. s. 10.9 ± 0.3 10.5 ± 0.2 n. s. 9.9 ± 2.5 9.8 ± 2.4 n. s.
Haematocrit (%) 39.9 ± 1.9 39.3 ± 3.3 n. s. 33.7 ± 1.4 31.0 ± 1.0 n. s. 31.4 ± 7.0 30.5 ± 5.7 n. s.
Platelets (× 103/μL) 94.3 ± 9.9 94.4 ± 11.5 n. s. 186.7 ± 23.9 192.5 ± 13.9 n. s. 186.3 ± 120.5 191.9 ± 123.0 n. s.
Lactate deydrogenase (IU/L) 228 ± 28.1 200.7 ± 21.4 n. s. 310.3 ± 57.4 272.0 ± 6.0 n. s. 285.9 ± 107.3 274.4 ±100.0 n. s.
Bleeding Days
Low Molecular Weight Heparin
(Days of bridging-therapy)
Red Blood Cell Units transfused 0 0 0 0 17 10 n. s.
Diapers (number)
Hospital admissions
(Days per month)
3.5 ± 0.5 2.2 ± 0.4 0.001 3.1 ± 0.5 2.2 ± 0.6 < 0.001 3.7 ± 0.7 2.5 ± 0.7 < 0.001
Reported data are the mean values and standard deviations of the evaluated parameters performed every month for twelve months during the treatment with
warfarin (W) and rivaroxaban (R)
Statistical analysis was performed using Student’s t-test. Significant level was set to p < 0.05. n. s. = not significant
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our five patients according to WHOQOL-BREF ques-
tionnaire [6] since one patient refused the interview
(Table 2). As for as the quality of life is concerned, the
total WHOQOL score was higher after rivaroxaban ther-
apy than before it, similarly scores for the physical (7
items), psychological (6 items), social relationship (3
items) and environment (8 items) domains. As concerns
the physical and psychological domains the increase in
QOL due to rivaroxaban was statistically significant.
After twelve months of therapy with rivaroxaban all pa-
tients with PNH refused to resume the previous treat-
ment with VKA.
The anticoagulant therapy in patients with PNH is
particularly complex since these patients can develop
the aplastic anemia with consequent thrombocytopenia
which increases bleeding risk above all in patients under
antithrombotic treatment. In addition, the multi-drugs
therapy in patients with PNH interferes with the man-
agement of antithrombotic therapy, although the throm-
bosis prophylaxis and treatment are mandatory for these
patients.
Until now, the experience on the use of direct oral
anticoagulant drugs in patients affected by PNH is low
and therefore, we suggested to discuss the use of these
new drugs in these specific patients.
Rivaroxaban is an orally active direct Factor Xa inhibi-
tor, which demonstrated to be effective in the prevention
of venous thromboembolism after orthopedic surgery
[7]. For people with non-valvular atrial fibrillation rivar-
oxaban was non-inferior to warfarin to prevent stroke or
embolism, with significant reduction in intracranial
haemorrhage and fatal bleeding [8]. Rivaroxaban can be
given in fixed doses and without routine anticoagulant
monitoring offering a less complex therapeutic regimen
for patient. The new direct oral anticoagulant drugs, anti
FIIa and FXa (Dabigatran, rivaroxaban, apixaban, and
edoxaban) are effective in the prophylaxis and treatment
of deep vein thrombosis and pulmonary embolism with
a low incidence of severe haemorrhagic complications
respect to VKA. In addition, recently low dose of rivar-
oxaban instead of the classical dosage was effective in re-
ducing recurrent venous thromboembolism among
patient who were in equipoise for continued anticoagu-
lation without to modify bleeding risk [9]. In agreement
with these data, it is interesting to note that the two pa-
tients with PNH who received a lower dose of rivaroxa-
ban (15 mg per day) did not have thrombotic
complications and did not interrupt the therapy for the
occurrence of adverse events during twelve months of
treatment.
These results suggest that rivaroxaban at the standard
dose or at the low dose could have a role in selected pa-
tients with a high risk to develop bleeding complications
during the treatment with antithrombotic drugs such as
patients affected by PNH.
The improvement in the quality of life observed in our
patients with PNH, who know very well the characteris-
tics of their disease, seems to be due to the awareness
that rivaroxaban therapy reduces significantly both se-
vere bleeding complications and days of hospitalization.
In conclusion this report suggests that rivaroxaban
therapy appears to be effective and safe in the treatment
of patients with PNH. Moreover, rivaroxaban was able to
ameliorate the quality of life in these specific patients.
However, further studies are needed to better evaluate
the role of new direct oral anticoagulants in patients
with PNH.
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Table 2 The World Health Organization Quality of Life (WHOQOL-BREF) after 12 months of anticoagulant treatment with warfarin
and rivaroxaban in the patients with paroxysmal nocturnal haemoglobinuria
Pt 1 Pt 2 Pt 3 Pt 4 All patients (n = 4) t-test
W R W R W R W R W R p
Total (26 items) 67 76 42 65 47 58 62 67 54.5 ± 11.9 66.5 ± 7.4 0.053
QOL rate (1 item) 25 75 50 50 25 25 25 75 31.3 ± 12.5 56.3 ± 23.9 n. s.
Satisfaction (1 item) 50 75 50 25 25 25 50 50 43.8 ± 12.5 43.8 ± 23.9 n. s.
Physical (7 items) 64 71 29 54 32 50 46 61 42.8 ± 16.0 59.0 ± 9.2 0.022
Psychological (6 items) 71 83 50 67 46 58 63 67 57.5 ± 11.6 68.8 ± 10.4 0.025
Social relationships (3 items) 83 83 50 67 92 92 67 75 73.0 ± 18.5 79.3 ± 10.7 n. s.
Environment (8 items) 69 72 44 81 50 59 78 72 60.3 ± 15.9 71.0 ± 9.1 n. s.
W Warfarin treatment; R Rivaroxaban treatment. Statistical analysis was performed using Student’s t-test
Significant level was set to p < 0.05. n. s. = not significant
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